Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148717 | 0.90 | GLRA1 (0.49) | GLRA1LMNAHPGDFFAR4RAB9A | |
| SCHEMBL21822979 | 0.89 | FFAR4 (0.46) | LMNAHPGDMCL1FFAR4MAPT | |
| SCHEMBL4566984 | 0.88 | MCL1 (0.54) | GLRA1LMNAMCL1FFAR4MAPT | |
| SCHEMBL12659923 | 0.87 | L3MBTL1 (0.53) | GLRA1LMNAMCL1FFAR4MAPT | |
| SCHEMBL1019564 | 0.85 | HPGD (0.49) | GLRA1LMNAHPGDRAB9AALDH1A1 | |
| SCHEMBL1018517 | 0.84 | GLRA1 (0.44) | GLRA1LMNAHPGDFFAR4ALDH1A1 | |
| SCHEMBL21327288 | 0.83 | LMNA (0.52) | LMNAHPGDMCL1FFAR4MAPT | |
| SCHEMBL1018714 | 0.82 | LMNA (0.53) | GLRA1LMNAHPGDMCL1MAPT | |
| SCHEMBL167312 | 0.82 | LMNA (0.49) | LMNAHPGDMCL1FFAR4MAPT | |
| SCHEMBL19667458 | 0.82 | FFAR4 (0.52) | LMNAHPGDMCL1FFAR4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-12-24 | — | — | US | disclosed |
| US-9206162-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | disclosed |
| US-9120745-B2 | Triazole compounds that modualte HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-9006277-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2012-05-17 | — | — | US | disclosed |
| US-20110319404-A1 | METHOD FOR TREATING NON-HODKIN'S LYMPHOMA | SYNTA PHARMACEUTICALS CORP. | 2011-12-29 | — | — | US | disclosed |
| US-20110319447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-29 | — | — | US | disclosed |
| US-8034834-B2 | Method for treating proliferative disorders with HSP90 inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-08-11 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | GLRA1 3446/4885LMNA 4608/4885HPGD 571/4885 |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, CDC37 | GLRA1 3514/4885LMNA 3414/4885HPGD 646/4885 |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 3902/4885LMNA 4005/4885HPGD 689/4885 |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | GLRA1 4278/4885LMNA 2220/4885HPGD 642/4885 |
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 3902/4885LMNA 4005/4885HPGD 689/4885 |
| US-20110319404-A1 | METHOD FOR TREATING NON-HODKIN'S LYMPHOMA | HSP90AB1, HSP90AA1, HSP90B1 | GLRA1 4244/4885LMNA 2509/4885HPGD 128/4885 |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 3902/4885LMNA 4005/4885HPGD 689/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | GLRA1 4278/4885LMNA 2220/4885HPGD 642/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | GLRA1 4211/4885LMNA 4425/4885HPGD 179/4885 |
| US-20110319447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 3902/4885LMNA 4005/4885HPGD 689/4885 |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 4595/4885LMNA 4672/4885HPGD 662/4885 |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 3902/4885LMNA 4005/4885HPGD 689/4885 |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 4005/4885LMNA 3854/4885HPGD 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.